WO2024060356A1 - 一种经济可行的工业化生产氘代新冠药物关键中间体的方法 - Google Patents
一种经济可行的工业化生产氘代新冠药物关键中间体的方法 Download PDFInfo
- Publication number
- WO2024060356A1 WO2024060356A1 PCT/CN2022/128507 CN2022128507W WO2024060356A1 WO 2024060356 A1 WO2024060356 A1 WO 2024060356A1 CN 2022128507 W CN2022128507 W CN 2022128507W WO 2024060356 A1 WO2024060356 A1 WO 2024060356A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deuterated
- covid
- key intermediate
- feasible method
- economically feasible
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 238000009776 industrial production Methods 0.000 claims abstract description 20
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract description 19
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 19
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000543 intermediate Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 229910052759 nickel Inorganic materials 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical group [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000007789 gas Substances 0.000 claims description 10
- -1 trimethylsilylethoxycarbonyl Chemical group 0.000 claims description 10
- 241000711573 Coronaviridae Species 0.000 claims description 9
- 239000012450 pharmaceutical intermediate Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 7
- 239000011903 deuterated solvents Substances 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- 239000005909 Kieselgur Substances 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052814 silicon oxide Inorganic materials 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 1
- 239000003759 ester based solvent Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000005265 energy consumption Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ISRXMEYARGEVIU-UHFFFAOYSA-N n-methyl-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C)C(C)C ISRXMEYARGEVIU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the field of drug synthesis, and specifically relates to an economically feasible method for industrial production of the key intermediate D of the deuterated COVID-19 drug.
- the new coronavirus SARS-CoV-2 is a new strain of coronavirus that has never been found in humans before. It was first discovered and reported in 2019. It is still prevalent in many countries around the world, and has not been widely recognized in many countries and regions. Good control.
- coronavirus Common signs of people infected with coronavirus include respiratory symptoms, fever, cough, shortness of breath and difficulty breathing. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure, and even death, and there is currently no specific treatment for the illness caused by the new coronavirus.
- the new deuterated cyano compound is a small molecule 3CL protease inhibitor independently developed by Shanghai Gusen Pharmaceutical Co., Ltd. By inhibiting the main protease, it can prevent the virus from cutting long protein chains into the parts required for self-replication. Its structure for: In vitro experiments have confirmed that it has amazing anti-SARS-CoV-2 activity and can effectively inhibit the replication of the virus. What is even more surprising is that on the basis of equivalent virus antibacterial activity, this compound has achieved better results than those of Pfizer and Merck.
- the developed oral anti-COVID-19 drug has better pharmacokinetic properties.
- Shanghai Gusen Pharmaceutical Co., Ltd. is preparing to conduct clinical trials for the treatment of COVID-19 patients. Once successful, the market prospects are huge.
- Shanghai Gusen Pharmaceutical Co., Ltd. has applied for an invention patent (application number CN202111234708X) for the above-mentioned new deuterated cyano compounds.
- the deuterated pharmaceutical intermediate D is a key intermediate for the synthesis of the above-mentioned new deuterated cyano compounds, and is also an important material for the synthesis of the GMP starting material E for the above-mentioned new coronavirus treatment drugs.
- the quality of its preparation process will also affect the quality of the final product. Quality and cost have a greater impact.
- the chemical formulas of deuterated pharmaceutical intermediates D and E are respectively:
- the present invention provides an economically feasible method for the industrial production of the key intermediate D of the deuterated COVID-19 drug.
- the preparation process of the present invention is simple, the catalyst is safe and easy to obtain, the cost is low, the yield is high, the purity is high, and the quality is controllable. Suitable for industrial production.
- reaction route is as follows:
- R1 and R3 are alkyl groups
- R2 is a protecting group
- compound B needs to be pretreated before the reaction.
- R1 and R3 are any one of methyl, ethyl, propyl, isopropyl and benzyl;
- R2 is any one of benzyloxycarbonyl, tert-butyloxycarbonyl, fluorenylmethoxycarbonyl, trimethylsilylethoxycarbonyl, p-toluenesulfonyl, acetyl, benzoyl, benzyl, 4-methoxybenzyl and trimethylsilylethoxy.
- the ester solvent is at least one of ethyl acetate, methyl acetate, isopropyl acetate, propyl acetate, butyl acetate, tert-butyl acetate, and isobutyl acetate.
- the ester solvent is selected from ethyl acetate.
- the solid-supported nickel main catalyst is nickel.
- the nickel content is 55 to 70%.
- the solid-loaded nickel carrier is at least one of diatomite, alumina, silicon oxide, and titanium oxide.
- the support is selected from alumina.
- the preparation method of the solid-loaded nickel is as follows: through precipitation and other techniques, the active ingredient nickel is highly dispersed on the carrier, and then the finished product is formed through processes such as filtration and washing, drying and roasting, reduction and passivation. See Figure 3 for a simplified flow diagram of a solid supported nickel preparation method.
- the organic base preferably contains ethylamine, diethylamine, triethylamine, diisopropylmethylamine, diisopropylethylamine, diisopropylamine, DBU, pyridine, piperidine, tetramethylguanidine, etc. At least one nitrogen-based organic base,
- At least one of triethylamine is preferred, and triethylamine is preferred.
- the content of the organic base is 1.0 to 2.0 equivalents, preferably 1.5 equivalents.
- the compound B is treated by washing with a combination of non-deuterated and deuterated solvents.
- the deuterated solvent in the above treatment method is selected from at least one of heavy water, deuterated alcohols, deuterated esters, deuterated hydrocarbons, and deuterated ethers, preferably heavy water;
- the non-deuterated solvent is selected from At least one selected from water, alcohols, esters, hydrocarbons, and ethers, preferably at least one selected from tetrahydrofuran, ethyl acetate, methylene chloride, methyltetrahydrofuran, and toluene.
- the weight ratio of the deuterated solvent to B in the above treatment method is at least 5%.
- the reaction temperature is 50°C to 80°C, preferably 75°C.
- the deuterium reaction pressure is 1.0-4.0MPa, preferably 2.0MPa.
- the present invention also protects the above-mentioned economically feasible method for industrial production of the key intermediate D of the deuterated new coronavirus drug in the preparation of the deuterated pharmaceutical intermediate E. role in.
- the present invention also protects the above-mentioned economically feasible method for industrial production of key intermediate D of deuterated new coronavirus drugs in the preparation of deuterated drugs. role in.
- reaction conversion rate and selectivity of the present invention are high, which greatly improves the reaction yield and deuterium abundance, reduces costs, and the yield can reach about 90%, and the product purity and deuterium abundance both reach more than 99%;
- reaction efficiency of the present invention is high, the reaction temperature is low, the energy consumption is low, and the reaction operation is simple;
- the synthesis route of the present invention avoids expensive deuterated solvents as reaction systems, has low cost, convenient post-processing, and is more suitable for industrial production.
- Figure 1 is the H NMR spectrum of deuterated pharmaceutical intermediate D.
- Figure 2 is the mass spectrum of deuterated pharmaceutical intermediate D.
- Compound B was pretreated with a dichloromethane/heavy water mixed solvent and then spun dry for later use.
- Compound B was pretreated with a mixed solvent of ethyl acetate/heavy water and then spun dry for later use.
- Compound B was pretreated with MeOD and then spun dry for later use.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,反应线路成本低廉,转化率、选择性高,反应收率、反应效率高、氘丰度高,能耗低,后处理方便,反应操作简单,更适合工业化生产。本发明可以高收率的制备得到中间体D,收率可达到95%左右,并且产品纯度及氘丰度都达到99%以上,达到药用级别。
Description
本发明属于药物合成领域,具体涉及一种经济可行的工业化生产氘代新冠药物关键中间体D的方法。
新型冠状病毒SARS-CoV-2是以前从未在人体中发现的冠状病毒新毒株,2019年首次被发现并报道,至今仍然在全球多个国家流行肆虐,并在很多国家区域并未得到很好的控制。
人感染了冠状病毒后常见体征有呼吸道症状、发热、咳嗽、气促和呼吸困难等。在较严重病例中,感染可导致肺炎、严重急性呼吸综合征、肾衰竭,甚至死亡,而且目前对于新型冠状病毒所致疾病没有特异治疗方法。
新型氘代氰基类化合物是由上海谷森医药有限公司独自研发的一种小分子3CL蛋白酶抑制剂,通过抑制主蛋白酶,可防止病毒将长蛋白链切割成其自我复制所需的部分,其结构为:
体外实验证实,其具有惊人的抗SARS-CoV-2活性,能有效抑制病毒的复制,更让人意外的是,该化合物在病毒抑菌活性相当的基础上,实现了比辉瑞、默克所研发的口服抗新冠药更优的药动学特质,目前,上海谷森医药有限公司已经准备进行临床试验用于治疗新冠病毒病患,一旦获得成功,市场前景非常巨大。而且,上海谷森医药有限公司针对上述新型氘代氰基类化合物申请了发明专利(申请号CN202111234708X)。
而氘代医药中间体D是合成上述新型氘代氰基类化合物的关键中间体,也 是合成上述新冠治疗药物的GMP起始物料E的重要物料,其制备工艺的优劣也将对终产品的质量及成本造成较大影响,氘代医药中间体D、E的化学式分别为:
尽管申请人在先专利CN202111234708X报道了氘代医药中间体D及其合成路线,即以化合物B为起始原料,在硼氘化钠和氯化钴的存在下,先经中间体态C,然后环合得到D。路线如下所示:
但以上路线未能提供中间体的质量说明,重复后发现中间体氘丰度较低,成本高,不适合放大生产,因生产需要,后续申请人专利CN2022100574053、CN2022109416337、CN2022110642358此路线基础上进行优化。路线如下所示:
以上路线如需获得高质量氘代度产品,都不可避免的需要使用大量氘代溶剂作为反应溶剂,氘代试剂成本高昂,使用量大,大大增加了生产成本,且目前国内氘代试剂基本依靠进口获得,如此大大制约了下游新冠药物-新型氘代氰基类化合物产业化实现。基于在国内疫情新冠药物的产业化需求下,药物研究高 质量要求下,开发出一条适合产业化的经济合成路线显得尤为重要。
发明内容
基于此,本发明提供了一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,本发明的制备工艺路线简单、催化剂安全易得、成本低廉、收率纯度高、质量可控、适合工业化生产。
具体技术方案如下:
在酯类溶剂中,化合物B在固载镍、有机碱、氘气的存在下发生氘代还原反应,得中间体D,反应路线如下:
其中,R1和R3为烷基,R2为保护基团,反应前需要对化合物B进行预处理。
2、优选地,所述R1、R3为甲基、乙基、丙基、异丙基、苄基其中任意一种;R2为苄氧羰基、叔丁氧羰基、芴甲氧基羰基、三甲基硅乙氧基羰基、对甲苯磺酰基、乙酰基、苯甲酰基、苄基、4-甲氧基苄基、三甲基硅基乙氧基中的任意一种。
所述酯类溶剂为乙酸乙酯、乙酸甲酯、乙酸异丙酯、乙酸丙酯、乙酸丁酯、乙酸叔丁酯、乙酸异丁酯的至少一种。
优选地,所述酯类溶剂选自乙酸乙酯。
所述固载镍主催化剂是镍。
所述镍的含量为55~70%。
所述固体负载镍载体为硅藻土、氧化铝、氧化硅、氧化钛中的至少一种。
优选地,所述载体选自氧化铝。
[根据细则91更正 05.05.2023]
所述固体负载镍制备方法为:通过沉淀等技术,将活性成分镍高度分散在载体上,再经过过滤洗涤、干燥焙烧、还原钝化等工序形成成品。参见图3的固体负载镍制备方法的简要流程图。
所述固体负载镍制备方法为:通过沉淀等技术,将活性成分镍高度分散在载体上,再经过过滤洗涤、干燥焙烧、还原钝化等工序形成成品。参见图3的固体负载镍制备方法的简要流程图。
[根据细则91更正 05.05.2023]
[已删除]
[已删除]
所述有机碱,优选乙胺、二乙胺、三乙胺、二异丙基甲胺、二异丙基乙胺、二异丙基胺、DBU、吡啶、哌啶、四甲基胍等含氮类有机碱的至少一种,
优选三乙胺的至少一种,优选三乙胺。
所述有机碱含量为1.0~2.0当量,优选1.5当量。
所述化合物B的处理方式为非氘代和氘代组合溶剂洗涤。
优选地,上述处理方式的氘代溶剂选自重水、氘代醇类、氘代酯类、氘代烃类、氘代醚类中的至少一种,优选重水;所述的非氘代溶剂选自水、醇类、酯类、烃类、醚类中的至少一种,优选四氢呋喃、乙酸乙酯、二氯甲烷、甲基四氢呋喃、甲苯中的至少一种。
优选地,上述处理方式的氘代溶剂与B的重量比至少为5%。
所述反应温度为50℃~80℃,优选75℃。
所述氘气反应压力为1.0~4.0MPa,优选2.0MPa。
本发明的氘代医药中间体D制备路线具有以下优点和有益效果:
(1)本发明中反应转化率、选择性高,极大提高了反应收率和氘丰度,降低成本,收率可达到90%左右,并且产品纯度及氘丰度都达到99%以上;
(2)本发明中反应效率高,反应温度低,能耗低,反应操作简单;
(3)本发明合成路线避免了昂贵氘代溶剂作为反应体系,成本低廉,后处理方便,更适合工业化生产。
图1为氘代医药中间体D的核磁氢谱图。
图2为氘代医药中间体D的质谱图。
以下结合具体实施例对本发明的采用固载镍催化工业化生产氘代医药中间体D的方法做进一步详细的说明。
以下详细的说明都仅是示例性和解释性的,而非限制性的。
以下实施例,除非另外指出,否则使用的所有溶剂和试剂都是商购得到并且以原样使用。
本文采用了以下缩写:
D
2:氘气
中间体D-1的合成
化学式:C
13H
20D
2N
2O
5
分子量:288.34
实施例1
将化合物B用二氯甲烷/重水混合溶剂预处理后旋干备用。
将处理后的B(1kg,3.2mol)加入到20L的氢化反应釜中,加入乙酸乙酯(10L,10V),加入氧化铝负载镍(镍含量63.5%,200g,20wt%of化合物B),加入三乙胺(485g,4.8mol);利用氮气和氘气依次置换2次,最后将氘气保压2.0Mpa;将体系温度升至75℃,保温反应5天。待反应到终点后,垫入硅藻土过滤,滤饼用乙酸乙酯进行淋洗。减压浓缩移除溶剂,所得粗品用10L二氯甲烷溶解。经5L的水进行洗涤1次,收集有机相。将有机相经无水硫酸钠干燥后,过滤,减压浓缩移除滤液中的溶剂。粗品经甲基叔丁基醚、石油醚和乙酸乙酯的混合溶液进行结晶纯化,过滤得到白色固体,纯度99.1%,收率90.0%,氘丰度99%。
实施例2
将化合物B用乙酸乙酯/重水混合溶剂预处理后旋干备用。
将处理后的B(1.0kg,3.2mol)加入到20L的氢化反应釜中,加入乙酸异丙酯(10L,10V),加入氧化铝负载镍(镍含量63.5%,200g,20wt%of化合物B),加入三乙胺(485g,4.8mol);利用氮气和氘气依次置换2次,最后将氘气保压2.0Mpa;将体系温度升至75℃,保温反应5天。待反应到终点后,垫入硅藻土过滤,滤饼用乙酸异丙酯进行淋洗。减压浓缩移除溶剂,所得粗品用10L二氯甲烷溶解。经5L的水进行洗涤1次,收集有机相。将有机相经无水硫酸钠干燥 后,过滤,减压浓缩移除滤液中的溶剂。粗品经甲基叔丁基醚、石油醚和乙酸乙酯的混合溶液进行结晶纯化,过滤得到白色固体,纯度98.9%,收率88.0%,氘丰度99%。
实施例3
将化合物B用MeOD预处理后旋干备用。
将处理后的B(0.5kg,1.6mol)加入到20L的氢化反应釜中,加入乙酸叔丁酯(5L,10V),加入氧化铝负载镍(镍含量63.5%,100g,20wt%of化合物B),加入三乙胺(243g,2.4mol);利用氮气和氘气依次置换2次,最后将氘气保压2.0Mpa;将体系温度升至75℃,保温反应5天。待反应到终点后,垫入硅藻土过滤,滤饼用乙酸叔丁酯进行淋洗。减压浓缩移除溶剂,所得粗品用10L二氯甲烷溶解。经5L的水进行洗涤1次,收集有机相。将有机相经无水硫酸钠干燥后,过滤,减压浓缩移除滤液中的溶剂。粗品经甲基叔丁基醚、石油醚和乙酸乙酯的混合溶液进行结晶纯化,过滤得到白色固体,纯度99.1%,收率88.5%,氘丰度99%。
LC-MS(ESI,m/z,C
13H
20D
2N
2O
5,189.17,[M+1]=M-100+1)
1H NMR(500MHz,CDCl
3)δ:5.72(s,1H),5.45(d,1H),4.32(m,1H),3.74(s,3H),2.45~2.46(m,2H),2.12~2.16(m,1H),1.82-1.85(m,2H),1.44(s,9H)。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (15)
- 据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:R1、R3为甲基、乙基、丙基、异丙基、苄基其中任意一种;R2为苄氧羰基、叔丁氧羰基、芴甲氧基羰基、三甲基硅乙氧基羰基、对甲苯磺酰基、乙酰基、苯甲酰基、苄基、4-甲氧基苄基、三甲基硅基乙氧基中的任意一种。
- 根据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述酯类溶剂为乙酸乙酯、乙酸甲酯、乙酸异丙酯、乙酸丙酯、乙酸丁酯、乙酸叔丁酯、乙酸异丁酯的至少一种,优选乙酸乙酯。
- 根据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述固载镍主催化剂是镍。
- 根据权利要求4所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述镍的含量为55~70%。
- 根据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中 间体D的方法,其特征在于:所述固体负载镍载体为硅藻土、氧化铝、氧化硅、氧化钛中的至少一种,优选氧化铝。
- 根据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述有机碱,优选乙胺、二乙胺、三乙胺、二异丙基甲胺、二异丙基乙胺、二异丙基胺、DBU、吡啶、哌啶、四甲基胍等含氮类有机碱的至少一种,优选三乙胺。
- 据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述有机碱用量为1.0~2.0当量,优选1.5当量。
- 根据权利要求1所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述化合物B预处理方式为氘代溶剂、非氘代和氘代组合溶剂洗涤。
- 根据权利要求9所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:所述的氘代溶剂选自重水、氘代醇类、氘代酯类、氘代烃类、氘代醚类中的至少一种,优选重水;所述的非氘代溶剂选自水、醇类、酯类、烃类、醚类中的至少一种,优选四氢呋喃、二氯甲烷、乙酸乙酯、甲基四氢呋喃、甲苯中的至少一种。
- 根据权利要求10所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:氘代溶剂与B的重量比至少为5%。
- 根据权利要求1-11任一项所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:反应温度为50~80℃,优选75℃。
- 根据权利要求1-12任一项所述的一种经济可行的工业化生产氘代新冠药物关键中间体D的方法,其特征在于:氘气反应压力为1.0~4.0MPa,优选2.0MPa。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211166133.7A CN116332819A (zh) | 2022-09-23 | 2022-09-23 | 一种经济可行的工业化生产氘代药物关键中间体的方法 |
CN202211166133.7 | 2022-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024060356A1 true WO2024060356A1 (zh) | 2024-03-28 |
Family
ID=86882769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/128507 WO2024060356A1 (zh) | 2022-09-23 | 2022-10-31 | 一种经济可行的工业化生产氘代新冠药物关键中间体的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116332819A (zh) |
WO (1) | WO2024060356A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114426568A (zh) * | 2022-01-11 | 2022-05-03 | 安帝康(无锡)生物科技有限公司 | 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途 |
CN114956934A (zh) * | 2022-01-20 | 2022-08-30 | 广州谷森制药有限公司 | 一种用于合成新型氘代氰基类化合物的中间体的制备方法 |
CN114957078A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种氘代医药中间体的制备方法 |
CN114957381A (zh) * | 2021-10-22 | 2022-08-30 | 广州谷森制药有限公司 | 新型氘代氰基类化合物、其制备方法、组合物及应用 |
-
2022
- 2022-09-23 CN CN202211166133.7A patent/CN116332819A/zh active Pending
- 2022-10-31 WO PCT/CN2022/128507 patent/WO2024060356A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957381A (zh) * | 2021-10-22 | 2022-08-30 | 广州谷森制药有限公司 | 新型氘代氰基类化合物、其制备方法、组合物及应用 |
CN114426568A (zh) * | 2022-01-11 | 2022-05-03 | 安帝康(无锡)生物科技有限公司 | 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途 |
CN114957078A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种氘代医药中间体的制备方法 |
CN114956934A (zh) * | 2022-01-20 | 2022-08-30 | 广州谷森制药有限公司 | 一种用于合成新型氘代氰基类化合物的中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116332819A (zh) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103333942B (zh) | 左旋吡喹酮的合成方法 | |
WO2023137874A1 (zh) | 一种氘代医药中间体的制备方法 | |
CN106083691B (zh) | 一种盐酸阿比朵尔一水合物的制备方法 | |
CN103788090B (zh) | 一种(1r,6s)-8-苄基-7,9-二氧代-2,8-二氮杂双环[4,3,0]壬烷的外消旋化方法 | |
CN101519428B (zh) | 一种l-丙氨酰-l-谷氨酰胺化合物及其合成方法 | |
CN102633686A (zh) | 一种帕拉米韦的制备方法 | |
US20220204529A1 (en) | Method for preparing lornoxicam | |
WO2023137876A1 (zh) | 一种用于合成新型氘代氰基类化合物的中间体的制备方法 | |
CN116640088A (zh) | 一种高纯度雷芬那辛的制备方法 | |
WO2024045292A1 (zh) | 一种采用固载镍与有机碱组合催化工业化生产氘代医药中间体的方法 | |
WO2024031838A1 (zh) | 一种采用固载镍催化工业化生产氘代医药中间体的方法 | |
WO2024060356A1 (zh) | 一种经济可行的工业化生产氘代新冠药物关键中间体的方法 | |
WO2013040750A1 (zh) | 制备β-蒿甲醚的方法 | |
CN111978328B (zh) | 一种替格瑞洛的合成方法 | |
CN108586517B (zh) | 一种碳青霉烯类抗生素药物中间体的合成方法 | |
CN112110926A (zh) | 一种制备替比培南酯的方法 | |
CN101412678B (zh) | 一种合成盐酸美金刚的方法 | |
CN109053721B (zh) | 一种药用丁溴东莨菪碱的制备方法 | |
CN114195684B (zh) | 一种氨基保护基n-取代手性氨基酸的合成方法 | |
CN116239529B (zh) | 一种二氧化碳参与的n-甲基四氢喹啉类生物碱的制备方法 | |
CN110143889B (zh) | 一种3-[(二甲基氨基)甲基]-5-甲基-2-己酮的合成方法 | |
CN112759590B (zh) | 一种莫西沙星的制备方法 | |
CN114507268B (zh) | 蟾酥甾二烯衍生物及其制备方法和应用 | |
CN115521964B (zh) | 一种甾体激素药物中间体的制备方法 | |
CN106916184B (zh) | 一种替诺福韦二吡呋酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22959358 Country of ref document: EP Kind code of ref document: A1 |